Give me quick revision of Chronic rhino sinusitis Allergic rhinitis Non allergic rhinitis Vasomotor rhinitis Complications of Chronic rhino sinusitis Management of CRS

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have sufficient material from the textbooks to compile a thorough quick revision. Let me put it all together.

Quick Revision: Rhinology Topics

1. Chronic Rhinosinusitis (CRS)

Definition

Persistent mucosal inflammation of the paranasal sinuses lasting >12 consecutive weeks, confirmed by nasal endoscopy and/or CT scan.

Diagnosis Requires (EPOS criteria - 2 major or 1 major + 2 minor symptoms):

Major symptoms:

Nasal obstruction/blockage
Anterior or posterior mucopurulent nasal discharge
Facial pain/pressure/fullness
Hyposmia/anosmia

Objective confirmation needed: CT scan OR nasal endoscopy (symptoms alone are unreliable - >40% with symptom-based CRS have normal CT and endoscopy).

Classification

Type	Key Feature
CRSsNP (without nasal polyps)	OMC obstruction driven; more neutrophilic inflammation
CRSwNP (with nasal polyps)	Eosinophilic inflammation; associated with asthma (26-40%), aspirin sensitivity

Pathophysiology

Persistent mucosal inflammation - multifactorial
Proposed mechanisms: staphylococcal superantigens, bacterial biofilms, aberrant immune response to fungi, microbial dysbiosis (loss of bacterial diversity with pathologic species overgrowth)
Bacteriology: S. aureus, Pseudomonas aeruginosa, anaerobes (unlike acute sinusitis)

CT Patterns (Babbel's 5 Patterns)

Infundibular (26%) - focal obstruction at maxillary ostium/ethmoid infundibulum
OMU pattern (25%) - ipsilateral maxillary + frontal + anterior ethmoid disease
Sphenoethmoidal recess (6%) - sphenoid/posterior ethmoid involvement
Sinonasal polyposis (10%) - diffuse polyps, infundibular enlargement, bulging ethmoid walls
Sporadic/unclassifiable - retention cysts, mucoceles

CT Findings

Mucosal thickening, partial/complete sinus opacification
Osteitis (bone thickening and sclerosis)
Intrasinus calcifications
Acute secretions: 10-25 HU; chronic/thickened: 30-60 HU
OMU opacification present in 72% of CRS patients

2. Allergic Rhinitis (AR)

Definition

IgE-mediated inflammation of the nasal mucosa triggered by specific allergens.

Epidemiology

Prevalence: 10-20% in USA and Europe; 6th most common chronic illness
Rising incidence - partly explained by the Hygiene Hypothesis (reduced early antigen exposure leads to exaggerated immune responses)

Classification

Seasonal - tree/grass pollens
Perennial - dust mites, pet dander
Episodic - intermittent exposures (e.g., visiting a pet-owning household)

Pathophysiology (Two-Phase Response)

Early Phase (within minutes):

Inhaled antigen recognized by IgE on mast cells/basophils
IgE cross-linking → mast cell degranulation
Release of histamine, tryptase, leukotrienes
Rhinorrhea, congestion, sneezing

Late Phase (4-8 hours later):

Chemoattractants recruit eosinophils, basophils, CD4+ lymphocytes, monocytes
Second wave of inflammatory mediators
Nasal congestion is the dominant symptom

Priming Effect: Repeated allergen exposure amplifies mucosal hyperresponsiveness over an allergy season.

Diagnosis

Skin prick testing or intradermal testing (risk of anaphylaxis - facilities must be prepared)
ImmunoCAP (specific IgE) - has largely replaced RAST; similar sensitivity to skin testing
Local Allergic Rhinitis - negative systemic testing but positive nasal allergen challenge (localized IgE production)

Treatment

Allergen avoidance
Intranasal corticosteroids - first-line for persistent AR
Oral/intranasal antihistamines (H1-blockers)
Leukotriene receptor antagonists (montelukast)
Immunotherapy (allergen desensitization) - subcutaneous or sublingual; modifies the disease course
Nasal saline irrigation
Omalizumab (anti-IgE) for severe/refractory cases

3. Non-Allergic Rhinitis (NAR)

Definition

Chronic nasal symptoms (congestion, rhinorrhea, postnasal drip) WITHOUT an IgE-mediated mechanism or infection, with negative allergy testing.

Key Distinguishing Features from AR:

Consistent symptoms (no seasonal variation)
No nasal or ocular pruritus (pruritus suggests AR)
No atopic history

Classification of NAR Types

Type	Key Features
Vasomotor/Idiopathic (IR)	Most common (71% of NAR); diagnosis of exclusion; environmental triggers
NARES	Eosinophilia >10% on nasal smear; negative IgE testing; severe symptoms
Hormonal rhinitis	Pregnancy, hypothyroidism, acromegaly, menopause
Drug-induced	NSAIDs, beta-blockers, ACEi, PDE-5 inhibitors, OCP, rhinitis medicamentosa
Occupational rhinitis	Workplace irritants; often with concurrent occupational asthma
Infectious rhinitis	Viral most common (rhinovirus, RSV, parainfluenza, adenovirus)
Smoke-induced	Neurogenic (substance P) + irritant mechanisms

4. Vasomotor Rhinitis (VMR)

Also Called: Idiopathic Rhinitis (IR), Nonallergic Rhinopathy (NAR)

Definition

A heterogeneous group of patients with chronic nasal symptoms that are not immunologic, infectious, or due to nasal eosinophilia - a diagnosis of exclusion.

Epidemiology

Most common subtype of NAR (71%)
Primarily adults with female predominance (2:1 to 3:1 F:M ratio)

Pathophysiology

Imbalance in autonomic innervation: parasympathetic predominance → vasodilation + mucosal edema
Historically thought purely neurogenic; now recognized as heterogeneous
Up to 25% convert to positive allergy testing on follow-up (overlap with AR exists)
Some patients show nasal hyperreactivity to cold air and histamine (overlap with NARES)

Triggers

Changes in temperature, humidity, barometric pressure
Strong odors (perfume, cooking, flowers, chemicals)
Environmental tobacco smoke
Alcohol ingestion
Exercise
Emotional factors
Symptoms may also occur spontaneously

Symptoms

Perennial or episodic nasal congestion and rhinorrhea (watery/clear)
No pruritus, no sneezing (distinguishes from AR)

Treatment

Trigger avoidance (first step)
Intranasal ipratropium bromide (anticholinergic) - best for watery rhinorrhea component; FDA approved for VMR
Intranasal corticosteroids (beclomethasone, fluticasone - FDA approved for NAR) - though weather-sensitive IR may respond poorly
Intranasal azelastine (topical antihistamine with anti-inflammatory properties) - effective; may mask bitter taste with sucralose
Combined azelastine + fluticasone spray - superior to monotherapy
Capsaicin nasal spray - desensitizes TRPV1 channels; used for idiopathic rhinitis
Oral antihistamines have limited role in pure VMR (more useful in NARES subtype)

5. Complications of Chronic Rhinosinusitis

Local Complications

Complication	Notes
Mucocele	Epithelial-lined mucus sac filling entire sinus; expansile, causes bony erosion; most common in frontal/ethmoid sinuses; Rx: endoscopic marsupialization
Pott Puffy Tumor	Frontal bone osteomyelitis with subperiosteal abscess and forehead swelling
Osteomyelitis	Bony wall destruction/sclerosis

Orbital Complications (Chandler Classification)

Stage	Description
I	Preseptal (periorbital) cellulitis - edema anterior to orbital septum
II	Orbital (postseptal) cellulitis - diffuse edema posterior to septum
III	Subperiosteal abscess - pus between periorbita and orbital wall
IV	Orbital abscess - pus within orbital fat; proptosis, chemosis, periorbital edema, ophthalmoplegia
V	Cavernous sinus thrombosis - bilateral signs, high fever, sepsis, cranial nerve palsies

Intracranial Complications

Meningitis
Epidural abscess
Subdural abscess (empyema)
Intracerebral abscess
Cavernous sinus thrombosis
Superior sagittal sinus thrombosis

Special Note - Fungal Sinusitis Complications

Immunocompromised patients (neutropenic, HIV, poorly controlled diabetes, transplant) at risk for acute invasive fungal sinusitis
Organisms: Aspergillus, Rhizopus, Mucor, Rhizomucor, Absidia
Endoscopy shows pale/black necrotic mucosa
Rapidly fatal if untreated; requires emergent surgical debridement + antifungals

When to Suspect Complication

Visual changes, mental status changes, neurologic changes
Proptosis, chemosis, periorbital edema
Requires contrast-enhanced CT + MRI
Prompt consultation: Otolaryngology + Ophthalmology + Neurosurgery

6. Management of CRS

Medical Management

Step 1 - First Line:

Agent	Role
Saline irrigation (hypertonic/isotonic)	Improves mucociliary clearance; reduces mucosal edema
Intranasal corticosteroids (INCS)	Anti-inflammatory; mainstay for CRSwNP and CRSsNP
Short-course oral corticosteroids	For significant polyp burden; induces rapid polyp shrinkage

Step 2 - Targeted/Add-On Therapy:

Agent	Role
Antibiotics (culture-guided)	Prolonged low-dose macrolides (for biofilm/anti-inflammatory effect) or course based on culture in CRSsNP
Antifungals	For allergic fungal rhinosinusitis (AFRS)
Leukotriene antagonists	Adjunct in aspirin-exacerbated respiratory disease (Samter's triad)

Samter's Triad: Nasal polyps + Asthma + Aspirin sensitivity - recalcitrant; aspirin desensitization can be considered.

Biologics (for severe CRSwNP refractory to steroids + surgery):

Dupilumab (anti-IL-4Rα) - FDA approved
Mepolizumab (anti-IL-5)
Benralizumab (anti-IL-5Rα)
Omalizumab (anti-IgE) - particularly for AFRS with atopy

Surgical Management - Functional Endoscopic Sinus Surgery (FESS/ESS)

Indications:

CRS recalcitrant to adequate medical therapy (most common indication)
Orbital or intracranial complications not responding to antibiotics
Mucoceles
Anatomic obstruction (e.g., antrochoanal polyp, severe deviated septum)
Recurrent acute rhinosinusitis (RARS)
Invasive/non-invasive fungal sinusitis
CSF rhinorrhea, meningoencephalocele

Principles:

CRSsNP: Relieve OMC obstruction, restore mucociliary drainage
CRSwNP: Complete ethmoidectomy; widen passages for topical drug delivery (virtually no penetration of topical agents into unoperated sinuses)
Surgery is adjunctive to medical therapy, not curative in most CRSwNP cases
Mucosa preservation and functional restoration are fundamental

Key Points:

Delay in surgery for CRSwNP adversely impacts sinonasal outcomes and asthma prevalence (UK studies)
Image-guided navigation systems help in difficult cases (mucoceles with skull base/orbital dehiscence)
ESS success rates for CSF rhinorrhea repair exceed 90%

Sources: Cummings Otolaryngology Head and Neck Surgery | Murray & Nadel's Textbook of Respiratory Medicine | K.J. Lee's Essential Otolaryngology | Mulholland & Greenfield's Surgery

This is a shared conversation. Sign in to Orris to start your own chat.